MARKET

GALT

GALT

Galectin Therapeutics Inc
NASDAQ
2.350
+0.050
+2.17%
After Hours: 2.400 +0.05 +2.13% 19:12 04/13 EDT
OPEN
2.290
PREV CLOSE
2.300
HIGH
2.450
LOW
2.260
VOLUME
219.48K
TURNOVER
--
52 WEEK HIGH
7.13
52 WEEK LOW
1.210
MARKET CAP
154.69M
P/E (TTM)
-4.8484
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GALT last week (0406-0410)?
Weekly Report · 20h ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 6d ago
Weekly Report: what happened at GALT last week (0330-0403)?
Weekly Report · 04/06 09:11
Galectin net loss narrows 34.4% to $31M in FY25
Reuters · 03/31 21:31
Galectin Therapeutics files $200M mixed securities shelf
TipRanks · 03/31 20:17
GALECTIN THERAPEUTICS INC - MAY OFFER UP TO $32.5 MLN COMMON STOCK UNDER ATM AGREEMENT WITH H.C. WAINWRIGHT - SEC FILING
Reuters · 03/31 20:12
Analysts Have Conflicting Sentiments on These Healthcare Companies: Terns Pharmaceuticals (TERN), Sangamo Therapeutics (SGMO) and Galectin Therapeutics (GALT)
TipRanks · 03/31 15:40
Galectin Therapeutics Q4 EPS $(0.08) Beats $(0.11) Estimate
Benzinga · 03/31 14:19
More
About GALT
Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.

Webull offers Galectin Therapeutics Inc stock information, including NASDAQ: GALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GALT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GALT stock methods without spending real money on the virtual paper trading platform.